Stonegate Investment Group LLC Sells 1,555 Shares of Pfizer Inc. (NYSE:PFE)

Stonegate Investment Group LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,747 shares of the biopharmaceutical company’s stock after selling 1,555 shares during the quarter. Stonegate Investment Group LLC’s holdings in Pfizer were worth $2,567,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Patrick M Sweeney & Associates Inc. raised its holdings in shares of Pfizer by 65.3% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 78,318 shares of the biopharmaceutical company’s stock valued at $2,078,000 after acquiring an additional 30,940 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. Buffington Mohr McNeal bought a new position in shares of Pfizer during the fourth quarter valued at approximately $331,000. Diamant Asset Management Inc. raised its holdings in shares of Pfizer by 19.4% during the fourth quarter. Diamant Asset Management Inc. now owns 10,165 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 1,650 shares in the last quarter. Finally, Cascade Investment Advisors Inc. raised its holdings in shares of Pfizer by 5.4% during the fourth quarter. Cascade Investment Advisors Inc. now owns 63,144 shares of the biopharmaceutical company’s stock valued at $1,675,000 after acquiring an additional 3,235 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 2.9 %

NYSE PFE opened at $26.86 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a market cap of $152.19 billion, a P/E ratio of 36.29, a P/E/G ratio of 0.64 and a beta of 0.64. The stock’s fifty day moving average price is $26.11 and its 200-day moving average price is $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period last year, the firm posted ($0.17) earnings per share. Pfizer’s revenue was up 31.2% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.